Ridding the body of HPV-infected cells is not as difficult as ridding the body of cancer cells…Remember, there are inhibitor proteins presented on cancer cells that prevent T-Cells from destroying them…HPV-infected cells have viral protein markers on cell surface that aren't as susceptible to this "self-inhibition" of T-Cells…The end points of the HPV 3100 P2 Trial are regression of CIN (Cervical Intraepithelial Neoplasia) 2/3 cells and clearance of HPV from patients…There is no need to show positive "survival" end points here…Just elimination of CIN 2/3 cells (and perhaps complete clearance of HPV)…Dr. Kim very confident, and has stated that they have gone after the "low-hanging fruit" so they don't have to get mired down in the FDA's cumbersome approval process requiring data that shows improvements in survival of cancer patients…Very wise people running INO!$ This vaccine will get orphan status and fast track status, and will position INO to make billions from this vaccine alone in just a few years (2-3?)…Get shares under $3 while they are a bargain!$
Sentiment: Strong Buy
This is a very good point and probably the most overlooked by anyone following INO. You can be sure there are lot of people who have something else completely different in mind whe it comes to what they believe INO is doing.
With that being said, I think we'll see more articles/pieces about this topic as we near the date for the results being published. I would only put it into the hands of someone like markbuti to get it out along with more of INO's "story". That would fill a lot of columns per page. So far, I've only read pieces from him and a few other authors that seem to have a good grasp on the INO story.